See more : Shore Bancshares, Inc. (SHBI) Income Statement Analysis – Financial Results
Complete financial analysis of Sensus Healthcare, Inc. (SRTS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sensus Healthcare, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Kinden Corporation (1944.T) Income Statement Analysis – Financial Results
- Relpol S.A. (RLP.WA) Income Statement Analysis – Financial Results
- SK Growth Opportunities Corporation (SKGR) Income Statement Analysis – Financial Results
- Jaxsta Limited (JXT.AX) Income Statement Analysis – Financial Results
- China TMK Battery Systems Inc. (DFEL) Income Statement Analysis – Financial Results
Sensus Healthcare, Inc. (SRTS)
About Sensus Healthcare, Inc.
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.41M | 44.53M | 27.04M | 9.58M | 27.26M | 26.43M | 20.59M | 14.81M | 10.27M | 5.81M | 10.48M |
| Cost of Revenue | 10.35M | 14.90M | 10.05M | 4.33M | 9.71M | 9.52M | 6.79M | 4.97M | 3.70M | 2.05M | 3.60M |
| Gross Profit | 14.06M | 29.63M | 16.99M | 5.25M | 17.56M | 16.91M | 13.80M | 9.85M | 6.57M | 3.76M | 6.88M |
| Gross Profit Ratio | 57.61% | 66.53% | 62.82% | 54.81% | 64.40% | 63.99% | 67.03% | 66.48% | 64.00% | 64.63% | 65.64% |
| Research & Development | 3.68M | 3.46M | 3.44M | 4.16M | 6.42M | 6.26M | 5.49M | 1.82M | 1.47M | 1.58M | 1.33M |
| General & Administrative | 5.16M | 5.01M | 4.59M | 3.99M | 4.00M | 4.12M | 3.72M | 3.47M | 1.59M | 1.65M | 1.45M |
| Selling & Marketing | 5.61M | 6.33M | 4.84M | 5.34M | 9.10M | 8.53M | 8.31M | 4.92M | 3.74M | 4.21M | 3.97M |
| SG&A | 10.76M | 11.34M | 9.43M | 9.33M | 13.11M | 12.66M | 12.03M | 8.38M | 5.33M | 5.86M | 5.42M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.44M | 14.80M | 12.87M | 13.48M | 19.53M | 18.92M | 17.52M | 10.21M | 6.80M | 7.44M | 6.75M |
| Cost & Expenses | 24.79M | 29.70M | 22.92M | 17.81M | 29.23M | 28.43M | 24.31M | 15.17M | 10.49M | 9.49M | 10.35M |
| Interest Income | 992.00K | 382.00K | 2.00K | 52.56K | 268.29K | 139.28K | 75.81K | 38.54K | 1.78K | 820.00 | 1.25K |
| Interest Expense | 0.00 | 2.00K | 1.00K | 14.23K | 0.00 | 156.69K | 68.88K | 21.87K | 17.79K | 20.03K | 20.47K |
| Depreciation & Amortization | 461.00K | 315.00K | 613.00K | 721.87K | 545.72K | 658.26K | 387.92K | 337.58K | 315.60K | 272.65K | 265.56K |
| EBITDA | 79.00K | 14.83M | 4.73M | -6.10M | -1.15M | -1.21M | -3.25M | 13.00K | 96.12K | -3.41M | 393.65K |
| EBITDA Ratio | 0.32% | 34.16% | 15.24% | -100.03% | -6.24% | -7.06% | -17.69% | -2.19% | 0.94% | -58.63% | 3.76% |
| Operating Income | -382.00K | 14.83M | 4.12M | -8.23M | -1.97M | -2.01M | -3.72M | -363.12K | -221.26K | -3.68M | 126.84K |
| Operating Income Ratio | -1.57% | 33.30% | 15.24% | -85.98% | -7.22% | -7.59% | -18.06% | -2.45% | -2.15% | -63.34% | 1.21% |
| Total Other Income/Expenses | 1.03M | 13.16M | -1.00K | 1.40M | 268.29K | -17.41K | 6.93K | 16.67K | -16.01K | -19.21K | -19.21K |
| Income Before Tax | 652.00K | 27.99M | 4.12M | -6.84M | -1.70M | -2.02M | -3.71M | -346.45K | -237.27K | -3.70M | 107.63K |
| Income Before Tax Ratio | 2.67% | 62.85% | 15.23% | -71.37% | -6.24% | -7.65% | -18.02% | -2.34% | -2.31% | -63.67% | 1.03% |
| Income Tax Expense | 167.00K | 3.75M | -613.00K | -2.12M | -545.72K | 139.28K | -312.11K | -299.05K | 1.78K | 820.00 | 1.25K |
| Net Income | 485.00K | 24.24M | 4.12M | -4.72M | -1.15M | -2.02M | -3.71M | -346.45K | -237.27K | -3.70M | 107.63K |
| Net Income Ratio | 1.99% | 54.44% | 15.23% | -49.24% | -4.23% | -7.65% | -18.02% | -2.34% | -2.31% | -63.67% | 1.03% |
| EPS | 0.03 | 1.47 | 0.25 | -0.29 | -0.07 | -0.14 | -0.28 | -0.03 | -0.02 | -0.37 | -0.04 |
| EPS Diluted | 0.03 | 1.46 | 0.25 | -0.29 | -0.07 | -0.14 | -0.28 | -0.03 | -0.02 | -0.37 | -0.04 |
| Weighted Avg Shares Out | 16.26M | 16.48M | 16.48M | 16.43M | 16.23M | 14.12M | 13.24M | 12.03M | 10.78M | 9.88M | 9.79M |
| Weighted Avg Shares Out (Dil) | 16.27M | 16.62M | 16.50M | 16.43M | 16.23M | 14.12M | 13.24M | 12.03M | 10.78M | 9.89M | 9.89M |
Sensus Healthcare to Host Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call on Thursday, February 8, 2024
Sensus Healthcare Announces Preliminary 2023 Revenue Exceeds $23 Million
Sensus Healthcare, Inc. (SRTS) Q3 2023 Earnings Call Transcript
Sensus Healthcare Reports Third Quarter 2023 Financial Results
Sensus Healthcare to Host Third Quarter 2023 Financial Results and Business Update Conference Call on Thursday, November 9, 2023
Sensus Healthcare to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference
Sensus Healthcare Sells Superficial Radiotherapy System to Cape Cod Hospital
7 ‘Strong Buy' Biotech Stocks to Rejuvenate Your Portfolio
Sensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San Diego
Sensus Healthcare Announces New $3 Million Share Repurchase Program
Source: https://incomestatements.info
Category: Stock Reports